ex.VAT:
VAT:
inc.VAT:

The unmissable event of this year
Friday, November 22, 2013Trends

L'Oréal stops CCB for short cosmetics

undefined

The latest cosmetic news: L'Oréal stops CCB - ANSM facilitates adverse reaction reporting - Amendment to CLP regulation - CSSC revises its Opinion on Methylene bis-benzotriazolyl tetramethylbutylphenol -"belle & bien" court contre le cancer - AFNOR : 4 compendiums of environmental signage standards - L'Oréal buys back Nickel - Triman postponed for one year - A further delayThe Colomer Group - New Board of Directors for Cosmébio - Death of Pierre Fabre - REACH : a reminder of the information obligation - China: Consultation for the approval of a new cosmetic ingredient - CLH consultation on hydroxyisohexyl 3-cyclohexene carboxaldehyde - India bans animal testing - FDA publishes its Guide to Good Manufacturing Practices - Cosmetic Regulations : a White Paper on the obligations of hairdressers - Retinol under study in Norway - REACH: the deadline of 31 May 2013 - Parliamentary fact-finding mission on environmental labelling…

Reading time
~ 37 minutes

November 22 - L'Oréal stops CCB The French cosmetics group L'Oréal announced on Tuesday 19 November its intention to stop the activity of its mail order subsidiary Beauté Créateurs during the first half of 2014. Created in the 1980s under the name Club des Créateurs de Beauté, this subsidiary now markets specific brands including Agnès b., Cosmence and Professor Christine Poelman. "Beauté Créateurs, which has achieved a turnover of 87 million euros over the last twelve months, mainly in France, has been experiencing difficulties for several years due to the structural weakening of the mail-order channel", explains L'Oréal in a press release.

November 8 - ANSM facilitates adverse reaction reporting Report an adverse reaction: what's new, asks the ANSM in an information point this November 7. And to answer:" A new section is available on the Agency's website to facilitate the reporting of adverse reactions suspected of being related to the use of a health product. Navigation by product type (medicines, medical devices, etc.), then by registrant (healthcare professional, patient, etc.), provides quick access to the appropriate form and practical information for completing it. The transmission of this declaration to the body responsible for collecting and managing alerts is also …

This content is only available to subscribersPREMIUM, STARTUP, PRO and TPE

Already subscribed?Log in

Discover our subscriptions

Your 2024 class program

TrendsOther articles